Indeed, higher serum levels of galectin-3 in individuals with IBD have been reported, yet these upregulated amounts of systemic galectin-3 did not effectively differentiate between active disease and remission in patients with UC and CD [145,146] (Table 1). This evidence concerns the gene LGALS3 and inflammatory bowel disease.